Information  X 
Enter a valid email address

Oxford Biomedica PLC (OXB)

  Print   

Tuesday 23 June, 2020

Oxford Biomedica PLC

Admission of shares and Total Voting Rights.

RNS Number : 8317Q
Oxford Biomedica PLC
23 June 2020
 

 

Oxford Biomedica

Admission of shares and Total Voting Rights

 

 

Oxford, UK - 23 June 2020: Oxford Biomedica plc ("Oxford Biomedica" or "the Company") (LSE: OXB), announces that further to the announcement made on 19 June 2020 regarding the Results of the Placing, the Company confirms that following admission to trading of the 5,000,000 Further Shares this morning, that its issued share capital now consists of 82,002,369 ordinary shares of 50p each. There are no Ordinary Shares held in treasury.

 

Accordingly, the total number of voting rights in Oxford Biomedica plc at the date of this notice is 82,002,369

 

The above figure 82,002,369 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Oxford Biomedica plc under the FCA's Disclosure Guidance and Transparency Rules.

 

-Ends-

 

For further information, please contact:

 

 

Oxford Biomedica plc:

Natalie Walter, Company Secretary

 

Tel: +44 (0)1865 783 000

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally, the group has signed a Clinical and Commercial Supply Agreement with AstraZeneca for manufacture of the adeno based COVID-19 vaccine candidate, AZN1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 550 people. Further information is available at  www.oxb.com .

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCFLFSVRVIVFII

a d v e r t i s e m e n t